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Mice with late-life systemic lupus erythematosus (SLE) backgrounds develop 
early,  severe  disease  when  subjected  to  various  accelerating  factors.  Similar 
immunostimulation of normal  mice leads to relatively innocuous autoimmune 
responses (1-4). 
This study asks the following questions: (a) Can the resistance of immunolog- 
ically normal mice to immunostimulation and pathogenic autoimmune responses 
be overcome by simultaneous action of multiple qualitatively different immuno- 
stimulating factors, and  (b)  if so,  what features distinguish the pathogenic vs. 
nonpathogenic autoimmune responses? We found that any single accelerating 
factor can  enhance the underlying autoimmune diseases in genetically predis- 
posed  mice,  but  simultaneous  stimulation  by  multiple  accelerating  factors  is 
required to induce pathogenic autoimmune responses in immunologically normal 
mice. The severity of pathogenic autoimmune responses correlates best with the 
total quantities of circulating immune complexes (CIC) and the fine characteris- 
tics of the autoantibodies rather than the magnitudes or multitudes of autoim- 
mune responses elicited. 
Materials and Methods 
MRL-lpr/lpr (lymphoproliferation gene homozygotes; MRL-Ipr), C57BL/6-lpr/lpr (B6- 
lpr),  and  C3H/HeJ-lpr/lpr  (C3H-lpr)  female mice were  originally developed at  The 
Jackson Laboratory (Bar Harbor, ME) (1) and bred further at the Scripps Mouse Colony. 
The non-lpr congenic MRL/n, B6, and C3H/HeJ mice were bred and maintained at the 
Scripps  Mouse Colony. Groups of 15 female mice of the three lpr substrains and their 
non-lpr congenic strains were studied. 
Five groups of mice (two lpr strains, B6-lpr and C3H-lpr,  and three non-lpr  strains, 
MRL/n, B6, C3H/HeJ) were injected intraperitoneally with the lipid-A portion of lipo- 
polysaccharide (LPS)  (R595,  purified from Salmonella minnesota; Caibiochem-Behring 
Corp., San Diego, CA) from 6 wk of age until moribund, or up to 10 mo, as previously 
described (3). Similar groups of unmanipulated mice served as controls. Histologic and 
serologic studies in the above groups of mice were performed as previously described (5, 
6). 
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TABLE  I 
Effects of lmmunostimulation  on Survival and Autoimmune Histopathologic Manifestations in 
Three Different Murine Strains 
Lymphoproliferation  Histopathology 
Murine strain  Mode of immu-  Age of 50% 
background  nostimulation  mortality  Lymphoid  Spleen mass  GN  Arthritis 
mass 
MRL/n 
C57BL/6 
CSH/H~ 
mo  g  g 
lpr  5.5  1.9  0.69  3-4+  2-3  + 
LPS  6.5  <0.1  0.45  3-4+  0 
None  17  <0.1  0.38  3-4+  1  + 
lpr + LPS  7.5  1.2  0.58  3-4+  0 
lpr  12  0.8  0.33  1-2+  0 
LPS  >12  <0.1  0.38  1-2+  0 
None  >17  <0.1  0.12  0  0 
lpr + LPS  >12  1.8  0.60  0-1+  0 
lpr  >12  1.7  0.58  0-1+  0 
LPS  >12  0.1  0.15  0  0 
None  >17  0.1  0.14  0  0 
In each group, autopsies were done on mice that appeared moribund (not necessarily due to GN), or at 12 or 17 
mo of age. The degree of lymphoproliferation and severity of histopathology in each group represent average 
values obtained with 15 mice. 
Results 
As  indicated  in  Table  I,  immunostimulation by  lpr accelerated  the  latent 
disease (giomerulonephritis [GN] and arthritis) of SLE-prone MRL/n mice (50% 
mortality reduced from  17 to 5.5 mo). In contrast, lpr had much less disease- 
inducing effect on C567BL/6 and C3H/HeJ  mice. Even at  12 mo, these mice 
had only mild GN and no arthritis, and did not die from kidney failure. 
Chronic immunostimulation by LPS accelerated the latent autoimmunity and 
GN (though not the arthritis) of MRL/n mice (50% mortality at 6.5 too), but 
induced much milder SLE in  LPS-responding normal mice (B6), and none in 
LPS-nonresponding normal mice (C3H/HeJ).  When subjected to simultaneous 
lpr and LPS immunostimulation, normal mice (B6) developed early-onset, fatal 
SLE (50% GN-associated mortality at 7.5 mo). 
The  total  lymphoid mass  (at  5  mo),  reflecting the  degree  of lpr-induced 
lymphoid hyperplasia, was highest in MRL-lpr, followed closely by C3H-lpr mice. 
B6-lpr mice had less  lymphoproliferation, although proliferation increases to 
comparable levels with age or simultaneous LPS treatment. LPS-induced lym- 
phoproliferation was manifested by weight increases in the spleen, rather than 
in lymph nodes. 
Each of lpr and LPS increased the total IgG in all three strains, except in the 
case of C3H/HeJ injected with LPS (Table II). In SLE-prone MRL/n mice, lpr 
induced the highest increases of IgG, particularly IgG1 and IgG2a, while LPS 
induced smaller increases, predominantly in IgG2b. In the two normal strains, 
lpr induced a smaller IgG increase, but the increase was in the same IgG subclasses 
as in MRL. In the LPS responder, B6, the LPS-associated increase was predom- 
inantly in the IgG2b subclass. With superimposed LPS stimulation, B6-lpr mice 
attained IgG levels nearly equivalent to MRL-lpr mice, but the predominant IgG 
isotype was IgG2b. 
In MRL mice, lpr markedly increased the total CIC and specifically increased HANG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLV.  II 
Effect of lmmunostimulation  on Serum lgG Isotypes,  Autoantibodies,  and IC 
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lsotype distribution*  Anti- 
Mode of  Total  single- 
Murine strain  immuno-  IgG*  stranded  gp70 IC 
background  stimulation  lgG1  IgG2a  IgG2b  DNA 
binding 
Total C1C 
MRL/n  ~r  34 
LPS  14 
None  8 
C57BL/6  ~r +  LPS  33 
fpr  t9 
LPS  12 
None  5 
C3H/HeJ  ~r +  LPS  18 
~r  17 
LPS  7 
None  6 
%  ~g/ml  ~g/ml' 
56  38  6  88 •  21  16 ± 3  >400 
36  21  43  49 ±  12  23 ± 6  70 ±  22 
50  32  18  18±10  5±2  12±2 
30  24  48  59 ± 21  11 ± 21  180 ±  112 
50  39  19  36 ±  10  3 ±  1  25 ± 40 
22  7  71  41±15  3±2  35±20 
50  24  26  6 ± 4  <1  <4 
44  36  19  46 ±  16  2 ±  1  22 ± 20 
41  39  18  42 ±  16  2 ±  1  20 ±  16 
41  34  25  5  ±  4  <1  <4 
47  33  22  6 ±  3  <1  <4 
Determinations  were done in 5-mo-old MRL-lpr  and MRL/n mice treated with LPS, 7-mo-old B6-1pr  given LPS, 
and C3H-lpr given LPS, and in ! 0-too-old B6-lpr, B6 given LPS, C3H-lpr, and C3H/HeJ mice given LPS. Values 
represent averages obtained with 15 mice per group. 
* Sum of all three igG subclasses measured by radial immunodiffusion. 
* Values expressed as percent of total IgG. 
! Micrograms aggregated mouse gamma globulin equivalents  per milliliter. 
TABLE  III 
Effect of lmmunostimulation  on lgM RF and Their lgG Subclass Specificities 
Murine strain  Mode of immu-  Total IgM 
background  nostimulation  Total lgM  RF 
lgM RF reacting with Ig6 subclasses* 
IgG  1  IgG2a  IgG2b  lgG3 
MRL/n 
tag/#l  #g[ml  #g]ml 
~r  286  48  18  45  19  16 
LPS  257  34  33  16  16  17 
None  160  10  6  9  6  6 
C57BL/6  ~r +  LPS  477  150  71  55  55  73 
lpr  590  370  310  150  27  205 
LPS  350  45  42  19  20  25 
None  120  5  5  5  4  5 
C3H/HeJ  Ipr + LPS  500  230  167  88  54  86 
lpr  480  270  197  87  66  95 
LPS  140  5  5  3  4  5 
None  120  4  5  4  4  5 
Determinations were done in 5-too-old  MRL-lpr and MRL/n mice given LPS, 7-mo-old  B6-lpr given LPS, and 
C3H-lpr given LPS,  and in  10-mo-old  B6-Ipr, B6 given LPS, C3H-Ipr and C3H/HeJ mice given LPS.  Values 
represent averages obtained with 15 mice per group. 
* Values >20 #g/ml were considered positive for IgM RF activity, since such levels  are not found in unmanipulated 
normal mice and other SLE mice lacking the lpr gene. 
levels of retroviral glycoprotein 70 immune complexes (gp 70 IC), whereas LPS 
induced  smaller  increases  (Table  II).  In  the  other  two strains,  each  immuno- 
stimulator raised the levels of these two complexes somewhat above unmanipu- 
lated controls.  In contrast, B6-lpr mice subjected to prolonged LPS stimulation 
showed significant CIC increases. 
Anti-single-stranded  DNA  autoantibodies  in  all  three  lpr  strains  were  in- 
creased over non-lpr controls,  the  highest  in  lupus-background  mice.  LPS in- 
creased  these  autoantibodies  in  the  two  LPS-responder  strains,  but  not  in 426  HANG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
nonresponder C3H/HeJ.  In MRL-lpr mice, most antibodies (70%) were IgG1 
and IgG2a, while they were mostly IgM in young, normal-background lpr and 
LPS-treated non-lpr mice. Analysis of 5-10 sera from young and old lpr mice 
revealed that the switch from IgM to IgG anti-single-stranded DNA autoanti- 
bodies occurred in 4-5-mo-old MRL-lpr mice, but was delayed to 10-12 mo of 
age in normal-background Ipr mice (data not shown). 
Total IgM and IgM rheumatoid factors (RF) increased in MRL-Ipr homozygous 
or  normal genetic background mice, and  in  LPS-responding mice.  The Ipr- 
induced IgM  RF were  higher in B6-1pr and C3H-lpr than  in MRL-lpr  mice 
(Table III). MRL-lpr RF represented 23% of the total IgM; B6-lpr and C3H-lpr 
RF comprised 62 and 59% of their total IgM, respectively-. Interestingly, chronic 
LPS treatment of B6-1pr mice reduced, rather than increased, IgM RF. MRL- 
lpr IgM RF exhibited higher reactivity with the IgG2a substrate, whereas B6-lpr 
and C3H-lpr IgM RF had higher anti-IgG1 activity. In the two responder strains, 
LPS induced polyclonal IgM RF that reacted primarily with IgG 1. 
Discussion 
The main findings of this study are:  (a)  Genetic background influences the 
specificities and  isotypes  of autoimmune responses and  the  distribution  and 
severity of immunopathology  caused by endogenous (lpr gene) and/or exogenous 
immunostimulating factors (LPS), and (b) Synergistic action of multiple immu- 
nostimulators can overcome the previously observed (2-5) "resistance" of normal 
mice to the induction of significant autoimmune disease. 
While the lpr gene accelerates latent GN and arthritis in SLE-prone MRL/n 
mice, LPS accelerates GN only. Differences in immunopathology  induced by two 
accelerators  acting  on  the  same  genetic  background might  be  explained by 
differences in  the cell  types stimulated and  in  the fine characteristics of the 
resulting immunologic responses. Thus, while the lpr gene promotes Thy-1 +, 
Lyt-1 + cell proliferation with enhanced helper activities (7),  LPS directly stimu- 
lates B cells.  Not surprisingly, the hypergammaglobulinemia and specificities of 
some induced autoantibodies differed. The increased IgG induced by lpr was 
primarily IgG1 and IgG2a, due to their strong T cell dependency (8). In contrast, 
LPS induced primarily IgG2b.  While most RF induced by lpr in the MRL/n 
mice were anti-IgG2a,  those stimulated by LPS were almost exclusively anti- 
IgG 1. Complementarity of anti;IgG2a RF with the abundant IgG2a autoantibod- 
ies in lpr homozygous, lupus-background mice (9) should increase the amount 
and size of CIC, possibly enhancing their pathogenicity. In contrast, little com- 
plementation could occur between RF and autoantibodies in LPS-treated MRL/ 
n mice and, therefore, the complexes formed may be less pathogenic. Moreover, 
proliferating T  cells in MRL-lpr mice might have arthritogenic activities and/or, 
the increased Ia expression detected (10) in macrophages of MRL-lpr mice might 
allow better self-antigen presentation to the T  cells infiltrating the synovium, 
thereby promoting tissue destruction. 
In  contrast  to  lupus-prone mice,  introduction of lpr or  LPS  into  normal- 
background mice failed to cause significant immunopathology. This was despite 
the induction of autoantibodies, as previously reported (4,  11). Higher amounts 
of autoantibodies and IC, and the earlier switch of autoantibodies from IgM to HANG ET  AL.  BRIEF  DEFINITIVE REPORT  427 
IgG may account for the severe immunopathology in lupus-prone, but not in 
normal mice. It is likely that activated B cells in lupus-background mice (7,  12) 
respond better to proliferation and differentiation factors secreted by the lpr- 
induced abnormal T  cells, thereby allowing a higher number of switching events. 
The lower levels of IgM RF in MRL-lpr mice (vs.  normal-background lpr/lpr 
mice) may be caused by the removal of MRL-lpr RF from the circulation after 
coupling with complementary IgG2a autoantibodies, which should not occur as 
efficiently  with  the  predominantly  anti-IgG1  RF  of  normal-background  lpr 
homozygotes. This possibility is supported by the observations that ~60% of the 
total IgM in normal-background lpr homozygous mice have RF activity, vs. 23% 
in MRL-lpr mice. 
The novel finding is that two simultaneously administered immunostimulators 
can  overcome  the  resistance  shown  by  B6  mice  to  induction  of  significant 
autoimmune disease by either stimulator alone. LPS-activated B6-lpr B cells may 
have an increased ability to receive and respond to lpr-induced antigen-nonspe- 
cific differentiation factors, which allows increased polyclonal Ig and autoanti- 
body production above threshold  levels.  In lupus-background (MRL/n)  mice, 
the apparently increased numbers of spontaneously activated B cells (9, 12) allows 
them to respond to lpr stimulation alone to attain their pathogenic potentials. 
Previous studies (13,  14) indicate that in vivo and in vitro lymphocytes from 
normal mice secrete autoantibodies spontaneously or after mitogenic stimulation. 
Idiotypes expressed  on autoantibodies  from lupus mice are  also  expressed  in 
normal mice (15) and, conversely, idiotypes of autoantibodies from normal mice 
can be found in lupus mice (16).  Despite this, the idiotype similarities may be 
only  partial,  or  caused  by  parallel  sets  of antibodies  without specificities  for 
autoantigens  (15),  and  do  not  necessarily  include  pathogenic  idiotypes.  Our 
findings indicate that most of the autoantibody variable region gene repertoire 
is represented in normal-background mice, but needs an appropriate stimulus or 
combinations of stimuli to be fully expressed. These findings complement recent 
protein  sequencing  (17)  and  molecular  cloning  (18,  19)  experiments  which 
suggest that the structural genetic elements of autoantibodies from lupus mice 
are closely related to those encoding antibodies to exogenous antigens in normal 
mice. 
Summary 
Either of two immunostimulating factors (lpr, lipopolysaccharide) enhanced 
the pathogenic autoimmune responses of MRL/n  mice, but the serologic and 
immunopathologic characteristics  differed.  In  contrast,  either  factor,  acting 
alone, caused minimal immunopathology in normal mice, despite autoantibody 
induction. Combined immunostimulation, however, caused fatal glomeruloneph- 
ritis  in  normal-background  C57BL/6  mice.  These  results  show the  profound 
influence of the background genome on the effects of immunostimulating agents, 
and show that resistance to autoimmune disease in immunologically normal mice 
is not absolute. 
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